Stefanie Dedeurwaerdere

Stefanie Dedeurwaerdere

Auto-generated profile, based on publicly available information

Stefanie Dedeurwaerdere

Department of Translational Neurosciences, University of Antwerp, Wilrijk, Belgium

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
KGKarolien Goffin
Karolien Goffin
SDStefanie Dedeurwaerdere
Stefanie Dedeurwaerdere
KLKoen Van Laere
Koen Van Laere
WPWim Van Paesschen
Wim Van Paesschen

1 November 2014 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
SMS. Missault
S. Missault
KEK. Van Den Eynde
K. Van Den Eynde
WBWim Vanden Berghe
Wim Vanden Berghe
EFE. Fransen
E. Fransen
AWA. Weeren
A. Weeren
SDS. Dedeurwaerdere
S. Dedeurwaerdere

1 July 2004 in Journal Of Clinical Neurophysiology
Verified
Journal Article
Closed access
KVKristl Vonck
Kristl Vonck
VTVijay Thadani
Vijay Thadani
KGKaren Gilbert
Karen Gilbert
SDStefanie Dedeurwaerdere
Stefanie Dedeurwaerdere
LGLiesbeth De Groote
Liesbeth De Groote
PBPaul Boon
Paul Boon
Vagus nerve stimulation (VNS) is an alternative treatment for medically or surgically refractory epilepsy. The long-term efficacy and safety of VNS were evaluated in a large patient series at Ghent University Hospital and Dartmouth-Hitchcock Medical Center. Between March 1995 and February 2003, seizure frequency and type as well as prescribed antiepileptic drugs and side effects were prospectively assessed in 131 patients treated with VNS in either center. Patients with a minimum follow-up duration of 6 months were included in the efficacy and safety analysis. A total of 118 of 131 implanted patients had a minimum postimplantation follow-up period of 6 months (mean, 33 months). The mean age of these patients was 32 years and the mean duration of refractory epilepsy was 22 years. The mean reduction in monthly seizure frequency in all patients was 55% (range, 0–100; SD = 31.6). Seven percent of patients were free of seizures with impaired consciousness, 50% of patients had a seizure frequency reduction of more than 50%, and 21% of patients were nonresponders. Fifteen patients reported stimulation-related side effects such as hoarseness or gagging. In a large patient series from two geographically distinct epilepsy centers located in two different continents, VNS proved to be efficacious and safe during long-term follow-up.

1 January 2014 in Behavioural Brain Research
Verified
Journal Article
Closed access
KEKarlien Van Den Eynde
Karlien Van Den Eynde
SMStephan Missault
Stephan Missault
EFErik Fransen
Erik Fransen
LRLeen Raeymaekers
Leen Raeymaekers
RWRoland Willems
Roland Willems
SDStefanie Dedeurwaerdere
Stefanie Dedeurwaerdere

1 January 2012 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
SDStefanie Dedeurwaerdere
Stefanie Dedeurwaerdere
PCPaul D Callaghan
Paul D Callaghan
TPTien Pham
Tien Pham
GRGita L Rahardjo
Gita L Rahardjo
HAHalima Amhaoul
Halima Amhaoul
MGMarie-Claude Grégoire
Marie-Claude Grégoire
Recently, inflammatory cascades have been suggested as a target for epilepsy therapy. Positron emission tomography (PET) imaging offers the unique possibility to evaluate brain inflammation longitudinally in a non-invasive translational manner. This study investigated brain inflammation during early epileptogenesis in the post-kainic acid-induced status epilepticus (KASE) model with post-mortem histology and in vivo with [18F]-PBR111 PET.

1 June 2016 in Neuropharmacology
Verified
Journal Article
Closed access
HAHalima Amhaoul
Halima Amhaoul
IAIdrish Ali
Idrish Ali
MMMarco Mola
Marco Mola
AEAnnemie Van Eetveldt
Annemie Van Eetveldt
KSKrystyna Szewczyk
Krystyna Szewczyk
SDStefanie Dedeurwaerdere
Stefanie Dedeurwaerdere